Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

N-LIfT PLATFORM PIPELINE

Our strategy is to initially target high unmet need solid tumours that qualify as rare (orphan) diseases where successful therapies can qualify for both Accelerated Regulatory Approval and Market Exclusivity Status.